Pulse Biosciences (PLSE) Hits New 52-Week Low at $10.29

Pulse Biosciences Inc (NASDAQ:PLSE)’s share price hit a new 52-week low on Thursday . The company traded as low as $10.29 and last traded at $10.42, with a volume of 598 shares. The stock had previously closed at $10.81.

A number of brokerages have weighed in on PLSE. BidaskClub raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. ValuEngine raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, July 2nd.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.54) earnings per share for the quarter.

Several institutional investors and hedge funds have recently bought and sold shares of PLSE. Silverleafe Capital Partners LLC bought a new stake in shares of Pulse Biosciences during the second quarter worth approximately $500,000. Bank of New York Mellon Corp raised its stake in shares of Pulse Biosciences by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 61,550 shares of the company’s stock worth $932,000 after buying an additional 5,127 shares during the last quarter. BlackRock Inc. raised its stake in shares of Pulse Biosciences by 23.0% during the second quarter. BlackRock Inc. now owns 600,109 shares of the company’s stock worth $9,085,000 after buying an additional 112,061 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Pulse Biosciences by 631.2% during the second quarter. Bank of America Corp DE now owns 16,101 shares of the company’s stock worth $244,000 after buying an additional 13,899 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Pulse Biosciences by 15.3% during the second quarter. Northern Trust Corp now owns 107,326 shares of the company’s stock worth $1,625,000 after buying an additional 14,231 shares during the last quarter. 9.64% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Featured Story: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply